These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18451222)

  • 1. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer.
    Ma XJ; Salunga R; Dahiya S; Wang W; Carney E; Durbecq V; Harris A; Goss P; Sotiriou C; Erlander M; Sgroi D
    Clin Cancer Res; 2008 May; 14(9):2601-8. PubMed ID: 18451222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease.
    Habel LA; Sakoda LC; Achacoso N; Ma XJ; Erlander MG; Sgroi DC; Fehrenbacher L; Greenberg D; Quesenberry CP
    Breast Cancer Res; 2013 Mar; 15(2):R24. PubMed ID: 23497539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.
    Ma XJ; Hilsenbeck SG; Wang W; Ding L; Sgroi DC; Bender RA; Osborne CK; Allred DC; Erlander MG
    J Clin Oncol; 2006 Oct; 24(28):4611-9. PubMed ID: 17008703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.
    Jerevall PL; Ma XJ; Li H; Salunga R; Kesty NC; Erlander MG; Sgroi DC; Holmlund B; Skoog L; Fornander T; Nordenskjöld B; Stål O
    Br J Cancer; 2011 May; 104(11):1762-9. PubMed ID: 21559019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer.
    Jankowitz RC; Cooper K; Erlander MG; Ma XJ; Kesty NC; Li H; Chivukula M; Brufsky A
    Breast Cancer Res; 2011 Oct; 13(5):R98. PubMed ID: 21999244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the two-gene ratio in breast cancer--independent roles for HOXB13 and IL17BR in prediction of clinical outcome.
    Jerevall PL; Brommesson S; Strand C; Gruvberger-Saal S; Malmström P; Nordenskjöld B; Wingren S; Söderkvist P; Fernö M; Stål O
    Breast Cancer Res Treat; 2008 Jan; 107(2):225-34. PubMed ID: 17453342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.
    Goetz MP; Suman VJ; Couch FJ; Ames MM; Rae JM; Erlander MG; Ma XJ; Sgroi DC; Reynolds CA; Lingle WL; Weinshilboum RM; Flockhart DA; Desta Z; Perez EA; Ingle JN
    Clin Cancer Res; 2008 Sep; 14(18):5864-8. PubMed ID: 18794098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.
    Jansen MP; Sieuwerts AM; Look MP; Ritstier K; Meijer-van Gelder ME; van Staveren IL; Klijn JG; Foekens JA; Berns EM
    J Clin Oncol; 2007 Feb; 25(6):662-8. PubMed ID: 17308270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer.
    Wang Z; Dahiya S; Provencher H; Muir B; Carney E; Coser K; Shioda T; Ma XJ; Sgroi DC
    Clin Cancer Res; 2007 Nov; 13(21):6327-34. PubMed ID: 17975144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study.
    Sgroi DC; Chapman JA; Badovinac-Crnjevic T; Zarella E; Binns S; Zhang Y; Schnabel CA; Erlander MG; Pritchard KI; Han L; Shepherd LE; Goss PE; Pollak M
    Breast Cancer Res; 2016 Jan; 18(1):1. PubMed ID: 26728744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of miR-1266 with recurrence/metastasis potential in estrogen receptor positive breast cancer patients.
    Sevinc ED; Egeli U; Cecener G; Tezcan G; Tunca B; Gokgoz S; Tasdelen I; Tolunay S; Evrensel T
    Asian Pac J Cancer Prev; 2015; 16(1):291-7. PubMed ID: 25640367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limits of predictive models using microarray data for breast cancer clinical treatment outcome.
    Reid JF; Lusa L; De Cecco L; Coradini D; Veneroni S; Daidone MG; Gariboldi M; Pierotti MA
    J Natl Cancer Inst; 2005 Jun; 97(12):927-30. PubMed ID: 15956654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen.
    Goetz MP; Suman VJ; Ingle JN; Nibbe AM; Visscher DW; Reynolds CA; Lingle WL; Erlander M; Ma XJ; Sgroi DC; Perez EA; Couch FJ
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2080-7. PubMed ID: 16609019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-gene expression ratio as predictor for breast cancer treated with tamoxifen: evidence from meta-analysis.
    Zhao L; Zhu S; Gao Y; Wang Y
    Tumour Biol; 2014 Apr; 35(4):3113-7. PubMed ID: 24264313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
    Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor-Positive Breast Cancer.
    Buechler SA; Gökmen-Polar Y; Badve SS
    Clin Breast Cancer; 2019 Feb; 19(1):17-26.e8. PubMed ID: 30097312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic Interaction of
    Sipeky C; Gao P; Zhang Q; Wang L; Ettala O; Talala KM; Tammela TLJ; Auvinen A; Wiklund F; Wei GH; Schleutker J
    Clin Cancer Res; 2018 Dec; 24(24):6265-6276. PubMed ID: 30181389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.
    Ma XJ; Wang Z; Ryan PD; Isakoff SJ; Barmettler A; Fuller A; Muir B; Mohapatra G; Salunga R; Tuggle JT; Tran Y; Tran D; Tassin A; Amon P; Wang W; Wang W; Enright E; Stecker K; Estepa-Sabal E; Smith B; Younger J; Balis U; Michaelson J; Bhan A; Habin K; Baer TM; Brugge J; Haber DA; Erlander MG; Sgroi DC
    Cancer Cell; 2004 Jun; 5(6):607-16. PubMed ID: 15193263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
    Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
    JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An 8-gene qRT-PCR-based gene expression score that has prognostic value in early breast cancer.
    Sánchez-Navarro I; Gámez-Pozo A; Pinto A; Hardisson D; Madero R; López R; San José B; Zamora P; Redondo A; Feliu J; Cejas P; González Barón M; Angel Fresno Vara J; Espinosa E
    BMC Cancer; 2010 Jun; 10():336. PubMed ID: 20584321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.